{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T20:39:09Z","timestamp":1771619949825,"version":"3.50.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/cad.0b013e32835a0fbd","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T09:40:35Z","timestamp":1350466835000},"page":"20-31","source":"Crossref","is-referenced-by-count":24,"title":["Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells"],"prefix":"10.1097","volume":"24","author":[{"given":"Bora","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun J.","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung S.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Y.","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210227","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia.","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"R2-3-20210227","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"R3-3-20210227","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/sj.onc.1203467","article-title":"The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6Abl) have altered substrate preferences and activate similar intracellular signalling pathways.","volume":"19","author":"Voss","year":"2000","journal-title":"Oncogene"},{"key":"R4-3-20210227","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/sj.onc.1203484","article-title":"JAK-STAT signaling activated by Abl oncogenes.","volume":"19","author":"Danial","year":"2000","journal-title":"Oncogene"},{"key":"R5-3-20210227","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0301-472X(03)00069-9","article-title":"Mechanisms of Bcr-Abl-mediated NF-kappaBRel activation.","volume":"31","author":"Kirchner","year":"2003","journal-title":"Exp Hematol"},{"key":"R6-3-20210227","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"R7-3-20210227","first-page":"8","article-title":"Chronic myeloid leukaemia in the 21st century.","volume":"76","author":"Frazer","year":"2007","journal-title":"Ulster Med J"},{"key":"R8-3-20210227","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"OBrien","year":"2003","journal-title":"N Engl J Med"},{"key":"R9-3-20210227","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"R10-3-20210227","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","article-title":"Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL() leukemic cells to the abl inhibitor STI571.","volume":"92","author":"Gambacorti-Passerini","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R11-3-20210227","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"R12-3-20210227","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.critrevonc.2005.06.007","article-title":"Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).","volume":"57","author":"Walz","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 1","key":"R13-3-20210227","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.leukres.2003.10.007","article-title":"Molecular mechanisms of resistance of leukemia to imatinib mesylate.","volume":"28","author":"Tauchi","year":"2004","journal-title":"Leuk Res"},{"key":"R14-3-20210227","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-199732050-00005","article-title":"Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.","volume":"32","author":"Lennernas","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"R15-3-20210227","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/01.CIR.0000056530.03783.81","article-title":"Suppression of the functionally coupled cyclooxygenase-2prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.","volume":"107","author":"Cipollone","year":"2003","journal-title":"Circulation"},{"key":"R16-3-20210227","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy.","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"R18-3-20210227","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nrc1751","article-title":"Statins and cancer prevention.","volume":"5","author":"Demierre","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R19-3-20210227","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/elps.1150170330","article-title":"Identification of human myocardial proteins separated by two-dimensional electrophoresis with matrix-assisted laser desorptionionization mass spectrometry.","volume":"17","author":"Thiede","year":"1996","journal-title":"Electrophoresis"},{"key":"R20-3-20210227","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1269\/jrr.11114","article-title":"Cell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells.","volume":"53","author":"He","year":"2012","journal-title":"J Radiat Res"},{"key":"R21-3-20210227","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/gut.2009.190900","article-title":"Effect of statin therapy on colorectal cancer.","volume":"59","author":"Bardou","year":"2010","journal-title":"Gut"},{"key":"R22-3-20210227","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ijc.23593","article-title":"Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice.","volume":"123","author":"Cho","year":"2008","journal-title":"Int J Cancer"},{"key":"R23-3-20210227","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cellsig.2009.12.010","article-title":"Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth.","volume":"22","author":"Ghosh-Choudhury","year":"2010","journal-title":"Cell Signal"},{"key":"R24-3-20210227","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-009-0507-x","article-title":"Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.","volume":"119","author":"Garwood","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R25-3-20210227","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.canlet.2006.10.009","article-title":"Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK.","volume":"250","author":"Koyuturk","year":"2007","journal-title":"Cancer Lett"},{"key":"R26-3-20210227","first-page":"3259","article-title":"Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways.","volume":"31","author":"Zhang","year":"2011","journal-title":"Anticancer Res"},{"key":"R27-3-20210227","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00008390-200504000-00001","article-title":"Lovastatin-induced apoptosis in human melanoma cell lines.","volume":"15","author":"Shellman","year":"2005","journal-title":"Melanoma Res"},{"key":"R28-3-20210227","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejphar.2011.09.031","article-title":"Involvement of Chk1-Cdc25A-cyclin ACDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells.","volume":"670","author":"Tu","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"R29-3-20210227","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.leukres.2004.10.007","article-title":"Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo.","volume":"29","author":"Lewis","year":"2005","journal-title":"Leuk Res"},{"key":"R30-3-20210227","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000158663","article-title":"In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells.","volume":"54","author":"Yang","year":"2008","journal-title":"Chemotherapy"},{"key":"R31-3-20210227","first-page":"612","article-title":"Effects of simvastatin on proliferation and apoptosis of acute monocytic leukemia cell line SHI-1.","volume":"19","author":"Li","year":"2011","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"R32-3-20210227","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1054\/bjoc.2000.1716","article-title":"Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.","volume":"84","author":"Kawata","year":"2001","journal-title":"Br J Cancer"},{"key":"R33-3-20210227","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejca.2004.12.013","article-title":"A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.","volume":"41","author":"Knox","year":"2005","journal-title":"Eur J Cancer"},{"key":"R34-3-20210227","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"R35-3-20210227","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"key":"R36-3-20210227","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCRABL-transformed hematopoietic cell lines.","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood"},{"key":"R37-3-20210227","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia - advances in biology and new approaches to treatment.","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"R38-3-20210227","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"R39-3-20210227","doi-asserted-by":"crossref","first-page":"33260","DOI":"10.1074\/jbc.272.52.33260","article-title":"The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr.","volume":"272","author":"Warmuth","year":"1997","journal-title":"J Biol Chem"},{"key":"R40-3-20210227","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.leu.2402778","article-title":"The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains.","volume":"17","author":"Stanglmaier","year":"2003","journal-title":"Leukemia"},{"key":"R41-3-20210227","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.1074\/jbc.M605902200","article-title":"Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.","volume":"281","author":"Meyn","year":"2006","journal-title":"J Biol Chem"},{"key":"R42-3-20210227","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res"},{"key":"R43-3-20210227","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/sj.leu.2403040","article-title":"Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.","volume":"17","author":"Miething","year":"2003","journal-title":"Leukemia"},{"key":"R45-3-20210227","first-page":"528","article-title":"Combination of simvastatin and imatinib sensitizes the CD34 cells in K562 to cell death.","volume":"28","author":"Chen","year":"2011","journal-title":"Med Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e32835a0fbd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:17:47Z","timestamp":1620947867000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201301000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32835a0fbd","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}